Acadian Asset Management LLC’s holdings in Exelixis were worth $3,267,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Source: https://www.dailypolitical.com/2023/11/12/acadian-asset-management-llc-raises-stock-holdings-in-exelixis-inc-nasdaqexel.html

AlphaCrest Capital Management LLC’s holdings in Exelixis were worth $2,750,000 at the end of the most recent quarter.

Source: https://www.americanbankingnews.com/2023/02/27/alphacrest-capital-management-llc-acquires-132670-shares-of-exelixis-inc-nasdaqexel.html

Comerica Bank’s holdings in Exelixis were worth $2,363,000 at the end of the most recent quarter.

Source: https://www.etfdailynews.com/2023/01/19/comerica-bank-sells-2075-shares-of-exelixis-inc-nasdaqexel/

Exelixis had a return on equity of 6.20% and a net margin of 9.24%.

Source: https://www.dailypolitical.com/2023/06/14/exelixis-inc-nasdaqexel-given-average-recommendation-of-moderate-buy-by-brokerages.html

Exelixis, Inc. has a 52-week low of $14.87 and a 52-week high of $23.40.

Source: https://www.etfdailynews.com/2023/01/19/comerica-bank-sells-2075-shares-of-exelixis-inc-nasdaqexel/

Finally, Ronald Blue Trust Inc. increased its position in Exelixis by 344.5% in the 4th quarter.

Source: https://www.americanbankingnews.com/2023/04/17/meritage-portfolio-management-has-6-81-million-stock-position-in-exelixis-inc-nasdaqexel.html

No, the principal risk that could knock Exelixis back is its biosimilar competition.

Source: https://seekingalpha.com/article/4570748-exelixis-stock-near-term-cautious-buy?source=feed_all_articles

These partnerships, in our view, are vital in further establishing Exelixis as a frontrunner in cancer treatment development.

Source: https://seekingalpha.com/article/4607873-exelixis-thriving-investment-opportunity-in-the-evolving-world-of-oncology?source=feed_all_articles